Abstract

Despite the controversial outcomes of clinical trials executed so far, the prevention of β-amyloid (Aβ) deposition and neurotoxicity by small molecule inhibitors of Aβ aggregation remains a target intensively pursued in the search of effective drugs for treating Alzheimer’s disease (AD) and related neurodegeneration syndromes. As a continuation of previous studies, a series of new 3-(2-arylhydrazono)indolin-2-one derivatives was synthesized and assayed, investigating the effects of substitutions on both the indole core and arylhydrazone moiety. Compared with the reference compound 1, we disclosed equipotent derivatives bearing alkyl substituents at the indole nitrogen, and fairly tolerated bioisosteric replacements at the arylhydrazone moiety. For most of the investigated compounds, the inhibition of Aβ40 aggregation (expressed as pIC50) was found to be correlated with lipophilicity, as assessed by a reversed-phase HPLC method, through a bilinear relationship. The N1-cyclopropyl derivative 28 was tested in cell-based assays of Aβ42 oligomer toxicity and oxidative stress induced by hydrogen peroxide, showing significant cytoprotective effects. This study confirmed the versatility of isatin in preparing multitarget small molecules affecting different biochemical pathways involved in AD.

Highlights

  • IntroductionAlzheimer’s disease (AD) is the most common cause of age-related neurodegenerative pathologies

  • Alzheimer’s disease (AD) is the most common cause of age-related neurodegenerative pathologies.AD represents a serious challenge for health systems, physicians and caregivers, because of its disabling course and the limited efficacy of pharmacological therapies [1]

  • Aβ peptide derives from proteolysis of precursor protein (APP) catalyzed by β- and γ-secretases, and is formed as 40- (Aβ40 ) or 42-mer amyloid precursor protein (APP) catalyzed by β- and γ-secretases, and is formed as 40- (Aβ40) or (Aβ42 )

Read more

Summary

Introduction

Alzheimer’s disease (AD) is the most common cause of age-related neurodegenerative pathologies. A typical feature of AD consists in the deposition of extracellular β-amyloid (Aβ) peptide aggregates (amyloid plaques), starting from cholinergic neurons of hippocampus and progressively extending to the whole brain cortex [4]. Aβ monomers in AD brains aggregate to soluble oligomers, that in turn lead to protofibrils and to the deposition of amyloid plaques [5]. As recently shown by our structure-activity relationship (SAR) studies [16,18], these taking place between Aβ and many classes of small molecules could be reinforced by polar interactions hydrophobic interactions taking place between Aβ and many classes of small molecules could be and/or hydrogen bond (HB) formation. For SARs, one ofincluding the most correlation of antiaggregating activity with lipophilicity, were investigated, and for one of the potent Aβ40 aggregation inhibitors (compound 28) cytoprotection from toxic Aβ42 oligomersmost in a potent. H (hetero)aromatic rings length and chemical nature of linker substitution on indole nitrogen length and chemical nature of linker

Chemistry substitution on
Chemistry
Reagents
Inhibition of Amyloid Aggregation
Aβ Antiaggregating
Left: Left
Kinetics of Aβ42 Fibrillization
Protection Assays Against Oxidative and Cytotoxic Effects
Cytoprotection compound
Synthesis of 3-arylhydrazono-indolin-2-ones 8 and 10
Synthesis of Compound 19
Synthesis of Carboxyhydrazide 23
3.1.10. Synthesis of 4-isopropylphenylhydrazonoindolin-2-ones 36–39
Determination of Llipophilicity by RP-HPLC
Inhibition of Aβ40 Aggregation
Cell-Based Assays
Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call